Article Details
Retrieved on: 2022-12-27 19:46:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
During the first nine months of 2022, Hemlibra was Roche's third highest-selling treatment, generating CHF 2.778 billion ($2.977 billion), up 28% from ...
Article found on: www.genengnews.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here